Washed Microbiota Transplantation Is Associated With Improved Lipid Profiles: Long-Term Efficacy and Safety in an Observational Cohort From South China

• Published in: Clinical and translational gastroenterology 2024-07, Vol.15 (7), p.e00735
• Main Authors: Liang, Fenfen, Song, Youlin, Lin, Dejiang, He, Hongxin, Xu, Jiating, He, Xingxiang, Wu, Lei
• Format: Article
• Language: English
• Subjects: Adult; Aged; Apolipoproteins; Cardiovascular disease; China - epidemiology; Cholesterol; Cholesterol, LDL - blood; Chronic illnesses; Clinical outcomes; Diabetes; Dyslipidemias - blood; Dyslipidemias - therapy; Fecal Microbiota Transplantation; Feces; Female; Functional GI Disorders; Gastroesophageal reflux; Gastrointestinal Microbiome; Hepatitis B; High density lipoprotein; Humans; Hyperlipidemia; Hyperlipidemias - blood; Hyperlipidemias - complications; Hyperlipidemias - therapy; Hypertension; Inflammatory bowel disease; Lipids; Lipids - blood; Lipoproteins; Male; Mann-Whitney U test; Medical screening; Metabolic disorders; Microbiota; Middle Aged; Obesity; Patients; Treatment Outcome; Triglycerides; Triglycerides - blood
• ISSN: 2155-384X; 2155-384X
• DOI: 10.14309/ctg.0000000000000735

Dyslipidemia is one of the main risk factors of chronic metabolic diseases. Our previous studies have shown that washed microbiota transplantation (WMT) has a significant improvement effect on patients with hyperlipidemia and hypolipemia in the Chinese population. The purpose of this study was to further explore the long-term efficacy and safety of WMT in patients with hyperlipidemia. Clinical data of patients who received WMT for multicourse were collected. Changes of blood lipid indexes before and after WMT, including triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein A, and Apolipoprotein B. A total of 124 patients were enrolled, including 56 cases in the hyperlipidemia group and 68 cases with normal lipids. The mean observation time was 787.80 ± 371.45 days, and the longest follow-up time was 1,534 days. TC and non-HDL-C in the hyperlipidemia group with 1-4 courses of WMT were significantly reduced ( P < 0.05); TG decreased significantly after the second course ( P < 0.05); low-density lipoprotein cholesterol also significantly decreased after the fourth course of treatment ( P < 0.05); TG, TC, and non-HDL-C significantly decreased in single course, double course, and multiple course, respectively ( P < 0.05). In terms of time period, over 1 year, the improvement in multicourse treatment was more significant than the single and double-course ones. In terms of comprehensive efficacy, WMT restored 32.14% of patients in the hyperlipidemia group to the normal lipid group ( P < 0.001), of which 30.00% recovered to the normal lipid group within 1 year ( P = 0.004) and 65.38% were reassigned to the normal lipid group over 1 year ( P = 0.003). In addition, over the 1-year treatment period, WMT significantly degraded the high-risk and medium-risk groups of atherosclerotic cardiovascular disease risk stratification in hyperlipidemia cases. There were no serious adverse events. WMT had a long-term improvement effect on patients with hyperlipidemia. The effect of multiple courses over 1 year was more significant than that of single/double courses and also had a significant destratification effect on the risk of atherosclerotic cardiovascular disease with high safety. Therefore, WMT provides a safe and long-term effective clinical treatment for patients with dyslipidemia.